





CTL/SAST/STAR/23-24/01152

June 14, 2023

BSE Limited	National Stock Exchange of India Limited.		
Phiroze Jeejeebhoy Towers	Exchange Plaza. C-1. Block G.		
Dalal Street.	Bandra Kurla Complex,		
Mumbai- 400001	Bandra(E), Mumbai – 400 051		
Strides Pharma Science Limited (Company)	Pronomz Ventures LLP (Pledgor)		
201, Devavrata, Sector 17, Vashi. Navi Mumbai – 400 703	Plot No. 30, 1st Main Road. J P Nagar, Third Phase Bangalore – 560078		

Dear Sir/Madam.

Sub: Disclosure pursuant to Regulation 29 (2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in relation release of Equity Shares of Strides Pharma Science Limited

Pursuant to the disclosure required to be made under Regulation 29 (2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, please find attached the disclosure in respect of release of Equity Shares of "Strides Pharma Science Limited" in favour of "Catalyst Trusteeship Limited" (formerly known as GDA Trusteeship Limited) in the capacity of Debenture Trustee for the benefit of the Debenture Holder(s) of Chayadeep Properties Private Limited.

For and on behalf of

Catalyst Trusteeship Ltd.

(Formerly known as GDA Trusteeship Limited)

Authorised Signatory

Name: Shane Fernandes

Designation: Manager

Encl: As above

9





ANNEXURE

Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

Name of the Target Company (TC)	Strides Pharma Science Limited Catalyst Trusteeship Limited (formerly GDA Trusteeship Limited) acting as Debenture Trustee of behalf Debenture Holder(s) of Chayadeep Properties Private Limited(CIN-U45203KA2003PTC094179).			
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer				
Whether the acquirer belongs to Promoter/Promoter group	No			
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited National Stock Exchange of India Limited			
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC(**)	
Before the acquisition under consideration, holding of acquirer along with PACs of:				
 a) Shares carrying voting rights b) Shares in nature of encumbrance (pledge/lien/non-disposal undertaking/others) c) Voting rights (VR) otherwise than by shares d) Warrants/convertible securities/ any other instrument that entities the acquirer to receive shares carrying voting rights in the TC (specify 	NIL 61.01.113 NIL	NIL 6.75% NIL	NIL 6.75 % NIL	
holding in each category) e) Total (a+b+c+d)	NIL 61.01.113	NIL 6.75 %	NIL 6.75 %	
Details of acquisition/sale:				
 a) Shares carrying voting rights acquired/sold b) VRs acquired/sold otherwise than by shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive 	NIL NIL	NIL NIL	NIL NIL	
shares carrying voting rights in the TC (specify holding in each category) acquired/sold d) Shares encumbered / invoked/released by the	NIL	NIL	NIL	
acquirer e) Total (a+b+c+t-d)	23.50.000 23.50.000	2.60% 2.60%	2.60% 2.60%	
After the acquisition/sale, holding of:			AND THE RESIDENCE OF THE PROPERTY OF THE PROPE	

CATALYST TRUSTEESHIP LIMITED


An ISO: 9001 Company





		Ţ	
 a) Shares carrying voting rights b) Shares encumbered with the acquirer c) VRs otherwise than by shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each 	NIL 37,51,113 NIL	NIL 4.15 % NIL NIL	NIL 4.15 % NIL NIL
category) after acquisition e) Total (a+b+c+d)	NIL 37,51,113	4.15 %	4.15 %
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc.)	By way of release of Equity Shares of Strides Pharma Science Limited kept as security for the issuance of the Non-Convertible Debentures.		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Ñ.A.		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	Date of Release – 27.03.2023 11.04.2023 27.04.2023 19.05.2023 13.06.2023		
Equity share capital / total voting capital of the TC before the said acquisition/ sale	Rs. 9,03.02,7040 (9.03.02.704 Equity Shares of Rs.10/ each)		

8



Delhi Office Office No. 810, 8th Floor, Kailash Building, 26, Kasturba Gandhi Marg, New Delhi - 110001 Tel +91 (11) 430 29101/02. CIN No. U74999PN1997PLC110262 Email dt@ctltrustee.com Website www.catalysttrustee.com







Equity share capital / total voting capital of the TC after the said acquisition/ sale	Rs. 9.03,02,7040 (9,03,02,704 Equity Shares of Rs.10/ each)	
Total diluted share / voting capital of the TC after the said acquisition / sale.	Rs. 9.03.02.7040 (9.03.02.704 Equity Shares of Rs.10/ each)	

Signature of the Acquirer:

For Catalyst Trusteeship Limited

(Formerly known as GDA Trusteeship Limited)

Authorized Signatory

Name: Shane Fernandes

emande

Designation: Manager

Place: Mumbai

Date: 14th June, 2023

Note:

(*) Total share capital/voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

CATALYST TRUSTEESHIP LIMITED

An ISO: 9001 Company